Skip to Main Content
Table 1.

Patient demographics and outcomes

Patient study numberSex (M/F)EthnicityAgeType of cancerActive disease sitesStageNumber of TCR transgenic cellsIL2 dosesDC dosesEvidence of transient tumor responseResponse at EOS (day 90)PFS (mo)OS (mo)Current status
F5-1 Caucasian 60 Melanoma Lung, stomach, liver, pancreas, peritoneum, soft tissues M1c 1 × 109 12/14 3/3 Yes by PET/CT PD Died of disease 
F5-3 Caucasian 61 Melanoma Lung, liver M1c 1 × 109 13/14 3/3 Yes by PET/CT SD 86 Died of disease 
F5-6 Caucasian 59 Melanoma Lung, LN M1b 1 × 109 13/14 3/3 Yes by PE SD Died of disease 
F5-7 Caucasian 48 Melanoma SC, bone M1c 1 × 109 9/14 3/3 Yes by CT SD 11 Died of disease 
F5-8 Caucasian 44 Melanoma LN, liver M1c 1 × 109 11/14 3/3 Yes by PET/CT SD 11 Died of disease 
F5-9 Caucasian 46 Melanoma Skin, LN M1a 1 × 109 11/14 3/3 No PD 20 Died of disease 
F5-12 Caucasian 40 Melanoma Lung, LN MIVb 3.9 × 109 6/9 3/3 Yes by PET/CT SD Died of disease 
F5-13 Caucasian 60 Melanoma Lung, abdomen, SC MIIIb 4.41 × 109 4/9 3/3 Yes by PET/CT SD Died of disease 
ESO-1 Hispanic 47 Liposarcoma Right renal fossa; liver left lobe; hepatic segment; peritoneal, perihepatic nodule IV 7.7 × 108 28/28 3/3 No PD 2.6 16 Died of disease 
ESO-3 Caucasian 24 Synovial sarcoma Right lung; multiple pulmonary nodules IV 1 × 109 19/28 1/3 Yes by PET/CT PR 67 67 Alive with CR 
ESO-4 Caucasian 41 Synovial sarcoma Left infraclavicular mass; left pectoralis mass III 1 × 109 18/28 3/3 Yes by PET/CT PD 25 Died of disease 
ESO-5 Caucasian 43 Synovial sarcoma Right popliteal fossa; lung IV 1 × 109 14/14 3/3 Yes by PET/CT PR 41.5 Died of disease 
ESO-6 Caucasian 26 Osteosarcoma Lung IV 1 × 109 14/14 3/3 Yes by PET/CT PD 2.5 19 Died of disease 
INY-2 Caucasian 66 Melanoma LN, liver IV 1 × 109 21/28 2/3 Yes by PET/CT PD Died of disease 
INY-3 Caucasian 44 Synovial sarcoma Right popliteal fossa; lung IV 1 × 109 14/14 3/3 Yes by PET/CT PD 31 Died of disease 
INY-4 Hispanic 24 Melanoma Lung, LN, adrenal gland, liver, trachea, brain IV 1 × 109 10/14 3/3 No PD NA Died of disease 
Patient study numberSex (M/F)EthnicityAgeType of cancerActive disease sitesStageNumber of TCR transgenic cellsIL2 dosesDC dosesEvidence of transient tumor responseResponse at EOS (day 90)PFS (mo)OS (mo)Current status
F5-1 Caucasian 60 Melanoma Lung, stomach, liver, pancreas, peritoneum, soft tissues M1c 1 × 109 12/14 3/3 Yes by PET/CT PD Died of disease 
F5-3 Caucasian 61 Melanoma Lung, liver M1c 1 × 109 13/14 3/3 Yes by PET/CT SD 86 Died of disease 
F5-6 Caucasian 59 Melanoma Lung, LN M1b 1 × 109 13/14 3/3 Yes by PE SD Died of disease 
F5-7 Caucasian 48 Melanoma SC, bone M1c 1 × 109 9/14 3/3 Yes by CT SD 11 Died of disease 
F5-8 Caucasian 44 Melanoma LN, liver M1c 1 × 109 11/14 3/3 Yes by PET/CT SD 11 Died of disease 
F5-9 Caucasian 46 Melanoma Skin, LN M1a 1 × 109 11/14 3/3 No PD 20 Died of disease 
F5-12 Caucasian 40 Melanoma Lung, LN MIVb 3.9 × 109 6/9 3/3 Yes by PET/CT SD Died of disease 
F5-13 Caucasian 60 Melanoma Lung, abdomen, SC MIIIb 4.41 × 109 4/9 3/3 Yes by PET/CT SD Died of disease 
ESO-1 Hispanic 47 Liposarcoma Right renal fossa; liver left lobe; hepatic segment; peritoneal, perihepatic nodule IV 7.7 × 108 28/28 3/3 No PD 2.6 16 Died of disease 
ESO-3 Caucasian 24 Synovial sarcoma Right lung; multiple pulmonary nodules IV 1 × 109 19/28 1/3 Yes by PET/CT PR 67 67 Alive with CR 
ESO-4 Caucasian 41 Synovial sarcoma Left infraclavicular mass; left pectoralis mass III 1 × 109 18/28 3/3 Yes by PET/CT PD 25 Died of disease 
ESO-5 Caucasian 43 Synovial sarcoma Right popliteal fossa; lung IV 1 × 109 14/14 3/3 Yes by PET/CT PR 41.5 Died of disease 
ESO-6 Caucasian 26 Osteosarcoma Lung IV 1 × 109 14/14 3/3 Yes by PET/CT PD 2.5 19 Died of disease 
INY-2 Caucasian 66 Melanoma LN, liver IV 1 × 109 21/28 2/3 Yes by PET/CT PD Died of disease 
INY-3 Caucasian 44 Synovial sarcoma Right popliteal fossa; lung IV 1 × 109 14/14 3/3 Yes by PET/CT PD 31 Died of disease 
INY-4 Hispanic 24 Melanoma Lung, LN, adrenal gland, liver, trachea, brain IV 1 × 109 10/14 3/3 No PD NA Died of disease 

Abbreviations: CR, complete response; DC, dendritic cells; EOS, end of study; F, female; LN, lymph nodes; M, male; mo, months; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SC, subcutaneous; SD, stable disease.

Close Modal

or Create an Account

Close Modal
Close Modal